Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Genzyme Buys Two Stem Cell Therapies
by Lisa M. Jarvis
November 10, 2008
| A version of this story appeared in
Volume 86, Issue 45
In a deal worth up to $1.3 billion, Osiris Therapeutics has licensed its lead adult stem cell treatments to Genzyme. Osiris granted Genzyme rights to Prochymal, a preparation of cells isolated from healthy bone marrow that is in Phase III trials for treating graft-versus-host disease and Crohn’s disease, and to Chondrogen, which is in a late-stage trial for treating osteoarthritis. In exchange Osiris snares a $130 million upfront payment and could reap hefty milestones and royalties.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X